
Check-Cap Ltd. CHEK
Annual report 2024
added 12-13-2025
Check-Cap Ltd. Total Assets 2011-2025 | CHEK
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Check-Cap Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 377 K | 25 M | 45.4 M | 55.7 M | 19.6 M | 9.43 M | 15.4 M | 7.91 M | 12.3 M | 15.3 M | 7.78 M | 5.38 M | 8.5 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 55.7 M | 377 K | 17.6 M |
Quarterly Total Assets Check-Cap Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 55.7 M | - | 32.6 M | - | 19.6 M | - | 17.9 M | - | 9.43 M | - | 15.9 M | - | 15.4 M | - | 20.8 M | - | 7.91 M | - | 10.1 M | - | 12.3 M | - | 10.7 M | - | 15.3 M | - | - | - | 2.98 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 55.7 M | 2.98 M | 17.6 M |
Total Assets of other stocks in the Diagnostics research industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
1.77 B | - | -17.87 % | $ 25.9 M | ||
|
Brainsway Ltd.
BWAY
|
94.3 M | $ 16.75 | -1.28 % | $ 99.4 M | ||
|
Burning Rock Biotech Limited
BNR
|
2.28 B | $ 16.9 | 7.3 % | $ 183 M | ||
|
Accelerate Diagnostics
AXDX
|
65 M | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
30.9 M | - | -13.05 % | $ 7.29 M | ||
|
BioNano Genomics
BNGO
|
76.7 M | $ 1.57 | -3.08 % | $ 2 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
235 M | - | - | $ 562 M | ||
|
Castle Biosciences
CSTL
|
531 M | $ 38.44 | -0.5 % | $ 1.07 B | ||
|
DarioHealth Corp.
DRIO
|
96.4 M | $ 12.0 | 0.93 % | $ 340 M | ||
|
Chembio Diagnostics
CEMI
|
62.6 M | - | 0.22 % | $ 16.8 M | ||
|
DexCom
DXCM
|
6.26 B | $ 66.39 | -0.85 % | $ 25.6 B | ||
|
Danaher Corporation
DHR
|
77.5 B | $ 226.5 | - | $ 166 B | ||
|
Exact Sciences Corporation
EXAS
|
5.93 B | $ 101.57 | 0.07 % | $ 18.8 B | ||
|
Fulgent Genetics
FLGT
|
1.22 B | $ 26.81 | -1.22 % | $ 811 M | ||
|
Global Cord Blood Corporation
CO
|
8.53 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
325 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
20.8 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
975 M | - | 0.12 % | $ 80.1 M | ||
|
DermTech
DMTK
|
122 M | - | -11.32 % | $ 2.94 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
4.18 B | - | - | $ 10.7 B | ||
|
CareDx, Inc
CDNA
|
467 M | $ 19.74 | -3.99 % | $ 1.06 B | ||
|
Celcuity
CELC
|
245 M | $ 102.0 | -3.09 % | $ 4.02 B | ||
|
Enzo Biochem
ENZ
|
85.8 M | - | -8.98 % | $ 14.8 K | ||
|
Anixa Biosciences
ANIX
|
21.6 M | $ 3.53 | -1.4 % | $ 113 K | ||
|
Co-Diagnostics
CODX
|
95.3 M | $ 0.31 | -9.4 % | $ 9.1 M | ||
|
Quidel Corporation
QDEL
|
1.87 B | $ 28.81 | 0.03 % | $ 1.21 B | ||
|
IQVIA Holdings
IQV
|
26.9 B | $ 222.3 | 0.04 % | $ 40.3 B | ||
|
Guardant Health
GH
|
1.49 B | $ 103.47 | 1.37 % | $ 12.7 B | ||
|
Aspira Women's Health
AWH
|
17.4 M | - | -6.19 % | $ 10.5 M | ||
|
Heska Corporation
HSKA
|
586 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
17.8 M | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
6.3 B | $ 133.88 | -0.73 % | $ 21.3 B | ||
|
Charles River Laboratories International
CRL
|
7.53 B | $ 196.14 | 1.64 % | $ 10.1 B | ||
|
Quotient Limited
QTNT
|
220 M | - | -11.32 % | $ 1.1 M | ||
|
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 183.36 | 0.47 % | $ 20.4 B | ||
|
Biodesix
BDSX
|
97.2 M | $ 7.56 | -3.63 % | $ 980 M | ||
|
Mettler-Toledo International
MTD
|
3.24 B | $ 1 410.24 | 1.17 % | $ 29.9 B | ||
|
Laboratory Corporation of America Holdings
LH
|
18.4 B | $ 262.29 | -0.71 % | $ 22 B | ||
|
Myriad Genetics
MYGN
|
1.03 B | $ 7.01 | -2.84 % | $ 635 M | ||
|
ICON Public Limited Company
ICLR
|
16.9 B | $ 183.39 | -1.71 % | $ 15.1 B | ||
|
IDEXX Laboratories
IDXX
|
3.29 B | $ 701.16 | -0.43 % | $ 57.8 B | ||
|
Lantheus Holdings
LNTH
|
1.98 B | $ 67.34 | 1.08 % | $ 4.66 B | ||
|
NeoGenomics
NEO
|
1.64 B | $ 12.07 | 1.81 % | $ 1.53 B | ||
|
Neogen Corporation
NEOG
|
3.44 B | $ 6.8 | -0.95 % | $ 1.47 B | ||
|
Agilent Technologies
A
|
10.7 B | $ 140.63 | 0.69 % | $ 42.8 B | ||
|
Biomerica
BMRA
|
5.94 M | $ 2.56 | 0.29 % | $ 5.88 M | ||
|
Bioventus
BVS
|
811 M | $ 7.59 | 0.53 % | $ 475 M | ||
|
Motus GI Holdings
MOTS
|
7.22 M | - | -34.28 % | $ 263 K |